Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of empagliflozin/metformin XR in healthy volunteers
NCT07266766Phase 1Completed
- Sponsor
- Humanis
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Curve from Time 0 to Last Collection Time at 72 hours. Started Aug 2025; status: completed.
02
Drugs
empagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07266766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266766.